Brief: Corbus Pharmaceuticals Announces FDA Clearance To Initiate Tempo-1 Registrational Study Of Crb-701 In Patients With 2L Oropharyngeal Cancer
28/07/2026 13:07
BRIEF-Corbus Pharmaceuticals Announces FDA Clearance To Initiate Tempo-1 Registrational Study Of Crb-701 In Patients With 2L Oropharyngeal Cancer July 28 (Reuters) - Corbus Pharmaceuticals Holdings Inc CRBP.O:
CORBUS PHARMACEUTICALS ANNOUNCES FDA CLEARANCE TO INITIATE TEMPO-1 REGISTRATIONAL STUDY OF CRB-701 IN PATIENTS WITH 2L OROPHARYNGEAL CANCER
CORBUS PHARMACEUTICALS ANNOUNCES FDA CLEARANCE TO INITIATE TEMPO-1 REGISTRATIONAL STUDY OF CRB-701 IN PATIENTS WITH 2L OROPHARYNGEAL CANCER
CORBUS PHARMACEUTICALS HOLDINGS INC: EXPECTS TO INITIATE ENROLLMENT IN TEMPO-1 IN SEPTEMBER 2026
Source text: ID:nGNX2bK0s
Further company coverage: CRBP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Corbus Pharmaceuticals Holdings
See all newsU.S. STOCKS ON THE MOVE-PBF Energy, Crown Castle, Definium Therapeutics
U.S. STOCKS ON THE MOVE-PBF Energy, Crown Castle, Definium Therapeutics
U.S. STOCKS ON THE MOVE-AI stocks, energy companies, Johnson & Johnson
U.S. STOCKS ON THE MOVE-US energy stocks, Baldwin, Johnson & Johnson
Corbus gains on weight-loss data for obesity drug in early-stage study